Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Darth Vader who wrote (70)	2/8/1998 10:09:00 AM
From: John S. Sturges	Read Replies (3) \| Respond to of 184

Red Flag!! PDLI's Zenapax is already approved(DEC '97) with no side-effects to replace Cyclosporin(one of SANG's products) and looks to just about eliminate transplant rejection episodes. Thymoglobulin is 2-3yrs from finishing a Phase III trial and has side effects which make it second rate as it is a rabbit serum product. This places most of SANG 's market at extreme risk. PDLI to present data on Feb 14th for auto-immune disease use and specifically on Feb 18th. for total elimination of Cyclosporin in transplant situations. PDLI's data is very, very strong as Zenapax is a humanized antibody and has no side effects. SANG just broke down technically!! Heavy insider selling!! Be careful of this one. Could fall sharply within 10days. Best regards, John